Vicore Pharma Holding AB ADR(VCRE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.04 | Insider Own | - | Shs Outstand | 28.1M | Perf Week | 5.12% |
| Market Cap | 0.27B | Forward P/E | - | EPS next Y | 14.96% | Insider Trans | - | Shs Float | - | Perf Month | 2.47% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -0.52 | Inst Own | - | Short Float | - | Perf Quarter | -14.2% |
| Income | -0.05B | P/S | 638.84 | EPS this Y | 11.53% | Inst Trans | 48.68% | Short Ratio | 0.05 | Perf Half Y | - |
| Sales | 0.00B | P/B | 3.11 | EPS next 5Y | 2.81% | ROA | -54.03% | Short Interest | 0.00M | Perf YTD | -34.53% |
| Book/sh | 3.13 | P/C | 2.94 | EPS past 3/5Y | 19.15% 6.64% | ROE | -58.46% | 52W High | -45.2% ($17.80) | Perf Year | - |
| Cash/sh | 3.32 | P/FCF | - | Sales past 3/5Y | - | ROIC | -60.81% | 52W Low | 23.79% ($7.88) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -11.59% | Gross Margin | - | Volatility(W/M) | 8.58% 7.34% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 421.21 | Sales Y/Y TTM | -42.16% | Oper. Margin | -13128.66% | ATR (14) | 0.68 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.68 | EPS Q/Q | -6.51% | Profit Margin | -12573.17% | RSI (14) | 52.01 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.68 | Sales Q/Q | 30.84% | SMA20 | 6.24% ($9.19) | Beta | - | Target Price | $28.07 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/21 | SMA50 | -4.65% ($10.24) | Rel Volume | 0.69 | Prev Close | $9.35 |
| Employees | 37 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -27.23% - | SMA200 | -11.05% ($10.97) | Avg Volume(3M) | 0.02M | Price | $9.76 |
| IPO | 2026/7/6 | Option/Short | No/Yes | Trades | 278 | Volume | 15,191 | Change | 4.33% |
🫁 폐섬유증과 호흡기 질환을 겨냥한 경구용 신약을 개발하는 임상 단계 바이오테크 기업입니다. 2000년 설립되어 스웨덴 스톡홀름에 본사를 두고 있으며, 안지오텐신 수용체 작용 기전을 활용한 질환 조절 치료제 개발에 집중하고 있습니다. 미국 예탁증서 형태로 거래됩니다.
Over the past 1 year, on the lower side
45% below its 1-year high.
Traded less than usual. That is 69% of its average volume.
VCRE has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +11.5% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $63,884. Peers typically go for $1,089.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Shareholder Composition Guide
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #270 of 594 in the industry
Based on market cap of $275M.
VOGX#269 Vogenx Inc $281M PER - VCRE#270 Vicore Pharma Holding AB ADR $275M PER - 
IPSC#271 Century Therapeutics Inc $272M PER - 
QTTB#272 Q32 Bio Inc $270M PER 3.0 
GLSI#273 Greenwich LifeSciences Inc $269M PER - 
FAQ
What kind of company is VCRE?
VCRE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VCRE?
The market cap of VCRE is approximately $275M, ranking 3,750 within its sector.
What is the 52-week high and low for VCRE?
VCRE has recorded a 52-week high of $17.80 and a low of $7.88.
